US4573995A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
Assignee: Alza Corp
•
Filing: 1984-10-09
•
Granted: 1986-03-04
•
Expires: 2004-10-09
Abstract
Abstract A method for transdermal delivery of naloxone, naltrexone and nalbuphine base through intact skin is described. Preferred embodiments of transdermal therapeutic systems for delivering these drugs and polyethylene glycol monolaurate employ an ethylene vinylacetate matrix containing drug base at a concentration above saturation and polyethylene glycol monolaurate below unit activity. Polyethylene glycol manolaurate is disclosed as a permeation enhancer for the base form of these drugs and is preferably delivered simultaneously with the drug.
Inventors
- 👤 Yu-Ling Chen
- 👤 Leslie L. Chun
- 👤 David J. Enscore
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 02:42
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/70; A61K9/7023; A61K9/703; A61K9/7084; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/47; A61K31/485; A61K47/00; A61K47/06; A61K47/08; A61K47/14; A61K9/0012; A61K9/0014
Claims Analysis
Total Claims: 41
Claim 1
Independent Claim
44 words
A composition of matter for the transdermal administration of a drug selected from the group consisting of naloxone, naltrexone and nalbuphine and mixtures thereof, comprising a matrix containing the base form of the drug and a skin permeation enhancing amount of polyethylene glycol monolaurate.
Claim 2
Dependent Claim
44 words
A composition of matter for the transdermal administration of a drug selected from the group consisting of naloxone, naltrexone and nalbuphine and mixtures thereof, comprising a matrix containing the base form of the drug and a skin permeation enhancing amount of polyethylene glycol monolaurate.
Claim 3
Dependent Claim
23 words
The composition of claim 1 wherein said drug base is present in an amount in excess of its saturation concentration in the matrix.
Claim 4
Dependent Claim
20 words
The composition of claim 1 wherein said polyethylene glycol monolaurate is present at an activity no greater than about 0.60.
Claim 5
Dependent Claim
13 words
The composition of claim 1 wherein said matrix comprises an ethylene vinylacetate copolymer.
Claim 6
Dependent Claim
16 words
The composition of claim 4 wherein said ethylene vinylacetate copolymer comprises about 28 to 60% vinylacetate.
Claim 7
Dependent Claim
25 words
The composition of claim 5 wherein the ethylene vinylacetate comprises 40% vinylacetate and the average molecular weight of the polyethylene glycol component is about 200.
Claim 8
Dependent Claim
16 words
The composition of claim 1, 2, 3, 4, 5 or 6 wherein said drug is naloxone.
Claim 9
Dependent Claim
16 words
The composition of claim 1, 2, 3, 4, 5 or 6 wherein said drug is naltrexone.
Claim 10
Dependent Claim
16 words
The composition of claim 1, 2, 3, 4, 5 or 6 wherein said drug is nalbuphine.
Claim 11
Dependent Claim
51 words
A transdermal therapeutic system comprising the composition of claims 1, 2, 3, 4, 5 or 6 in combination with: (a) an occlusive backing behind the skin distal surface of said reservoir composition and (b) means for maintaining said reservoir composition in drug and polyethylene glycol monolaurate transferring relationship to human skin.
Claim 12
Independent Claim
54 words
A method for the transdermal administration of a drug selected from the group consisting of naloxone, naltrexone and nalbuphine and mixtures thereof which comprises placing a source of the base form of the drug in drug transmitting relationship to the skin in the presence of a drug permeation enhancing amount of polyethylene glycol monolaurate.
Claim 13
Independent Claim
54 words
A method for the transdermal administration of a drug selected from the group consisting of naloxone, naltrexone and nalbuphine and mixtures thereof which comprises placing a source of the base form of the drug in drug transmitting relationship to the skin in the presence of a drug permeation enhancing amount of polyethylene glycol monolaurate.
Claim 14
Dependent Claim
14 words
The method of claim 11 wherein the source of drug is at unit activity.
Claim 15
Dependent Claim
14 words
The method of claim 11 wherein said polyethylene glycol monolauroleate is below unit activity.
Claim 16
Dependent Claim
22 words
The method of claim 13 wherein the initial activity of said PEGML in said source is within the range of about 0.25-0.60.
Claim 17
Dependent Claim
26 words
The method of claim 11 wherein drug is delivered through the skin at a rate of about 20-40 μg/hr/cm 2 for an extended period of time.
Claim 18
Independent Claim
42 words
A method of the transdermal delivery of a drug selected from the group consisting of naloxone, naltrexone, nalbuphine and mixtures therof which comprises delivering the drug in base form through intact skin for an extended period of time at a therapeutic rate.
Claim 19
Independent Claim
42 words
A method of the transdermal delivery of a drug selected from the group consisting of naloxone, naltrexone, nalbuphine and mixtures therof which comprises delivering the drug in base form through intact skin for an extended period of time at a therapeutic rate.
Claim 20
Dependent Claim
19 words
The method of claim 16 wherein the therapeutic rate is in the range of about 20-40 μg/cm 2 /hr.
Claim 21
Dependent Claim
10 words
The method of claim 16 wherein said drug is naloxone.
Claim 22
Dependent Claim
10 words
The method of claim 16 wherein said drug is naltrexone.
Claim 23
Dependent Claim
10 words
The method of claim 16 wherein said drug is nalbuphine.
Claim 24
Dependent Claim
77 words
A medical device for the transdermal delivery of a material selected from the group consisting of naloxone, naltrexone and nalbuphine comprising in combination: (a) reservoir means containing a skin permeable formulation containing said material; (b) an occlusive backing behind the skin distal surface of said reservoir means and extending beyond the periphery of said reservoir means; and (c) an adhesive overlay disposed on the skin distal surface of said occlusive backing and extending beyond the periphery thereof.
Claim 25
Dependent Claim
77 words
A medical device for the transdermal delivery of a material selected from the group consisting of naloxone, naltrexone and nalbuphine comprising in combination: (a) reservoir means containing a skin permeable formulation containing said material; (b) an occlusive backing behind the skin distal surface of said reservoir means and extending beyond the periphery of said reservoir means; and (c) an adhesive overlay disposed on the skin distal surface of said occlusive backing and extending beyond the periphery thereof.
Claim 26
Dependent Claim
12 words
The transdermal therapeutic system of claim 21, wherein said drug is naloxone.
Claim 27
Dependent Claim
12 words
The transdermal therapeutic system of claim 21, wherein said drug is naltrexone.
Claim 28
Dependent Claim
12 words
The transdermal therapeutic system of claim 21, wherein said drug is nalbuphine.
Claim 29
Dependent Claim
73 words
A medical device for the transdermal administration of a material selected from the group consisting of naloxone, naltrexone, and nalbuphine through intact skin for an extended period of time at a therapeutic rate substantially greater than 0.1 μg/cm 2 /hour, which comprises: (a) a unit activity reservoir of a skin permeable form of said material, said reservoir comprising a carrier having said material substantially uniformly distributed there through at a concentration above saturation;
Claim 30
Dependent Claim
73 words
A medical device for the transdermal administration of a material selected from the group consisting of naloxone, naltrexone, and nalbuphine through intact skin for an extended period of time at a therapeutic rate substantially greater than 0.1 μg/cm 2 /hour, which comprises: (a) a unit activity reservoir of a skin permeable form of said material, said reservoir comprising a carrier having said material substantially uniformly distributed there through at a concentration above saturation;
Claim 31
Dependent Claim
38 words
(b) a reservoir of a skin permeation enhancer for said material, and (c) means for maintaining said material reservoir and said permeation enhancer reservoir in material and permeation enhancer transferring relationship to the same area of intact skin.
Claim 32
Dependent Claim
38 words
(b) a reservoir of a skin permeation enhancer for said material, and (c) means for maintaining said material reservoir and said permeation enhancer reservoir in material and permeation enhancer transferring relationship to the same area of intact skin.
Claim 33
Dependent Claim
17 words
The medical device of claim 25, wherein said permeation enhancer reservoir is combined with said material reservoir.
Claim 34
Dependent Claim
47 words
The medical device of claim 25, wherein said permeation enhancer comprises polyethylene glycol monolaurate at an activity no greater than about 0.6, and said reservoir contains polyethylene glycol monolaurate in an amount sufficient to maintain the activity thereof above about 0.25, throughout said extended period of time.
Claim 35
Dependent Claim
38 words
The medical device of claim 25 wherein said skin permeable form of said material is the base form and said material reservoir contains sufficient material to maintain the activity at unit activity throughout said extended period of time.
Claim 36
Dependent Claim
40 words
The medical device of claim 25, further comprising means for controlling the rate of release of permeation enhancer from said enhancer reservoir to said material reservoir, and said material reservoir is disposed between said rate controlling means and the skin.
Claim 37
Dependent Claim
82 words
The medical device of claim 25, wherein said permeation enhancer comprises polyethylene glycol monolaurate and said reservoir contains polyethylene glycol monolaurate at an activity no greater than about 0.6 and in an amount sufficient to maintain the activity above about 0.25 throughout the said extended time period, said material reservoir contains the base form of said material at a concentration above saturation in an amount sufficient to maintain the concentration of said material at least at the saturation level throughout said period.
Claim 38
Dependent Claim
19 words
The medical device of claim 25, further comprising an impermeable backing on the skin distal side of said reservoir.
Claim 39
Independent Claim
118 words
A method for the transdermal delivery of a drug selected from the group consisting of naloxone, naltrexone and nalbuphine at a therapeutic rate substantially greater than 0.1 μg/cm 2 /hr for an extended period of time which comprises: (a) contacting an area of intact skin with a source of a skin permeable form of said drug at unit activity and a skin permeation enhancer for said drug at a permeation enhancing concentration, (b) maintaining said source in drug and permeation enhancer transmitting contact with the skin for said extended period of time; and (c) maintaining the source of said drug at unit activity and said permeation enhancer at a permeation enhancing concentration for said extended period of time.
Claim 40
Independent Claim
118 words
A method for the transdermal delivery of a drug selected from the group consisting of naloxone, naltrexone and nalbuphine at a therapeutic rate substantially greater than 0.1 μg/cm 2 /hr for an extended period of time which comprises: (a) contacting an area of intact skin with a source of a skin permeable form of said drug at unit activity and a skin permeation enhancer for said drug at a permeation enhancing concentration, (b) maintaining said source in drug and permeation enhancer transmitting contact with the skin for said extended period of time; and (c) maintaining the source of said drug at unit activity and said permeation enhancer at a permeation enhancing concentration for said extended period of time.
Claim 41
Dependent Claim
19 words
The method of claim 32 wherein said therapeutic rate is in the range of 20-40 μg/hr/cm 2 of skin.
References Cited (Backward Citations)
US4141897A
Cited
US4201211A
Cited
US4460372A
Cited
US4464378A
Cited
US4435180A
Cited
US4493848A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-03-03 | 1989-09-02 | 1990-03-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-03-03 | 1993-09-02 | 1994-03-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-03-03 | 1997-09-02 | 1998-03-04 | $7700.00 | Window Closed / Lapsed |